RELMADA THERAPEUTICS, INC. Realized Investment Gains (Losses)
RELMADA THERAPEUTICS, INC. (RLMD) reported Realized Investment Gains (Losses) of -$37.29 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for the quarter ending 2026-06-30 was -$37.29K, a 179.01% decline year-over-year.
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for the quarter ending 2026-03-31 was -$9.87K, a 115.67% decline year-over-year.
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for the quarter ending 2025-12-31 was -$107.92K, a 364.23% decline year-over-year.
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for the quarter ending 2025-09-30 was -$81.44K, a 155.09% decline year-over-year.
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for fiscal 2025 was -$79.21K, a 121.13% decline from fiscal 2024.
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for fiscal 2024 was $374.93K.
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for fiscal 2023 was -$4.06M.
- RELMADA THERAPEUTICS, INC. realized investment gains (losses) for fiscal 2022 was -$585.52K.
| Period end | Realized Investment Gains (Losses) 3 month | Realized Investment Gains (Losses) 6 month | Realized Investment Gains (Losses) 9 month | Realized Investment Gains (Losses) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$37.29K 10-Q · filed 2026-08-06 | -$47.16K 10-Q · filed 2026-08-06 | -$155.09K derived: sum of 3 quarters · filed 2026-08-06 | -$236.52K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$9.87K 10-Q · filed 2026-05-12 | -$117.79K derived: sum of 2 quarters · filed 2026-05-12 | -$199.23K derived: sum of 3 quarters · filed 2026-05-12 | -$152.03K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$107.92K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$189.36K derived: sum of 2 quarters · filed 2026-03-19 | -$142.16K derived: sum of 3 quarters · filed 2026-08-06 | -$79.21K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$81.44K 10-Q · filed 2025-11-13 | -$34.23K derived: sum of 2 quarters · filed 2026-08-06 | $28.72K 10-Q · filed 2025-11-13 | $69.56K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $47.20K 10-Q · filed 2026-08-06 | $110.16K 10-Q · filed 2026-08-06 | $151.00K derived: sum of 3 quarters · filed 2026-08-06 | $298.83K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $62.95K 10-Q · filed 2026-05-12 | $103.80K derived: sum of 2 quarters · filed 2026-05-12 | $251.63K derived: sum of 3 quarters · filed 2026-05-12 | $384.75K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $40.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $188.68K derived: sum of 2 quarters · filed 2026-03-19 | $321.79K derived: sum of 3 quarters · filed 2026-03-19 | $374.93K 10-K · filed 2026-03-19 |
| 2024-09-30 | $147.84K 10-Q · filed 2025-11-13 | $280.95K derived: sum of 2 quarters · filed 2025-11-13 | $334.08K 10-Q · filed 2025-11-13 | -$3.01M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $133.11K 10-Q · filed 2025-08-07 | $186.25K 10-Q · filed 2025-08-07 | -$3.16M derived: sum of 3 quarters · filed 2025-08-07 | -$3.21M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $53.13K 10-Q · filed 2025-05-12 | -$3.29M derived: sum of 2 quarters · filed 2025-05-12 | -$3.34M derived: sum of 3 quarters · filed 2025-05-12 | -$3.34M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$3.40M derived: sum of 2 quarters · filed 2025-03-27 | -$3.40M derived: sum of 3 quarters · filed 2025-03-27 | -$4.06M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$51.71K 10-Q · filed 2024-11-07 | -$51.71K derived: sum of 2 quarters · filed 2024-11-07 | -$718.42K 10-Q · filed 2024-11-07 | -$751.77K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$666.71K 10-Q · filed 2024-08-07 | -$700.06K derived: sum of 3 quarters · filed 2024-08-07 | -$1.26M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$666.71K 10-Q · filed 2024-05-08 | -$700.06K derived: sum of 2 quarters · filed 2024-05-08 | -$1.26M derived: sum of 3 quarters · filed 2024-05-08 | -$1.24M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$33.35K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$595.00K derived: sum of 2 quarters · filed 2024-03-19 | -$570.50K derived: sum of 3 quarters · filed 2024-03-19 | -$585.52K 10-K · filed 2024-03-19 |
| 2022-09-30 | -$561.65K 10-Q · filed 2023-11-08 | -$537.15K derived: sum of 2 quarters · filed 2023-11-08 | -$552.17K 10-Q · filed 2023-11-08 | -$674.85K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $24.50K 10-Q · filed 2023-08-08 | $9.48K 10-Q · filed 2023-08-08 | -$113.20K derived: sum of 3 quarters · filed 2023-08-08 | -$450.15K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$15.02K 10-Q · filed 2022-05-05 | -$137.71K derived: sum of 2 quarters · filed 2023-03-23 | -$474.65K derived: sum of 3 quarters · filed 2023-03-23 | -$598.25K derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | -$122.68K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$459.63K derived: sum of 2 quarters · filed 2023-03-23 | -$583.22K derived: sum of 3 quarters · filed 2023-03-23 | -$636.01K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$336.95K 10-Q · filed 2022-11-10 | -$460.54K derived: sum of 2 quarters · filed 2022-11-10 | -$513.33K 10-Q · filed 2022-11-10 | -$424.57K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$123.59K 10-Q · filed 2022-08-11 | -$176.38K 10-Q · filed 2022-08-11 | -$87.62K derived: sum of 3 quarters · filed 2022-08-11 | -$173.79K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$52.79K 10-Q · filed 2022-05-05 | $35.97K derived: sum of 2 quarters · filed 2022-05-05 | -$50.20K derived: sum of 3 quarters · filed 2022-05-05 | -$37.39K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $88.76K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $2.59K derived: sum of 2 quarters · filed 2022-03-25 | $15.40K derived: sum of 3 quarters · filed 2022-03-25 | -$156.21K 10-K · filed 2022-03-25 |
| 2020-09-30 | -$86.17K 10-Q · filed 2021-11-12 | -$73.36K derived: sum of 2 quarters · filed 2021-11-12 | -$244.97K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $12.81K 10-Q · filed 2021-08-10 | -$158.80K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$171.61K 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |